Choline pivaloyl ester strengthened the benefit effects of Tacrine and Galantamine on electroencephalographic and cognitive performances in nucleus basalis magnocellularis-lesioned and aged rats

Pharmacology Biochemistry and Behavior

Volumn 84, Issue 3, 2006, Pages 453-467

  Rispoli, V ^a   Marra, R ^b   Costa, N ^a   Scipione, L ^c   Rotiroti, D ^a   De Vita, D ^c   Liberatore, F ^c   Carelli, V ^c  

^a Department of Pharmacobiological Sciences   (Italy)

^b INSTITUTE OF NEUROLOGICAL SCIENCES   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Alzheimer's disease; Choline; Cholinergic neurotransmission; Cholinesterase inhibitors; Cognitive behavioural functions; Combined treatment; Electroencephalography

Indexed keywords

CHOLINE PIVALOYL ESTER; CHOLINESTERASE INHIBITOR; GALANTAMINE; TACRINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITION; DRUG EFFECT; ELECTROENCEPHALOGRAM; ELECTROENCEPHALOGRAPHY; LOCOMOTION; MAGNOCELLULAR NUCLEUS; MALE; MAZE TEST; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RAT; TASK PERFORMANCE;

ANIMALS; BEHAVIOR, ANIMAL; CHOLINE; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ELECTROENCEPHALOGRAPHY; ENZYME INHIBITORS; GALANTAMINE; MALE; RATS; RATS, WISTAR; SCOPOLAMINE; TACRINE;

ANIMALIA;

EID: 33748712915     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2006.06.009     Document Type: Article

References (98)

1. Alkondon M., and Albuquerque E.X. Presence of alpha-bungarotoxin-sensitive nicotinic acetylcholine receptors in rat olfactory bulb neurons. Neurosci Lett 176 2 (1994) 152-156
2. Alkondon M., Pereira E.F., Cortes W.S., Maelicke A., and Albuquerque E.X. Choline is a selective agonist of alpha7 nicotinic acetylcholine receptors in the rat brain neurons. Eur J Neurosci 9 12 (1997) 2734-2742
3. Allen N.H.P., and Burns A. The treatment of Alzheimer's disease. J Psychopharmacol 9 (1995) 43-56
4. Arendt T., Lehman K., Saeger G., and Gartner U. Synergistic effects of tetrahydroaminoacridine and lithium on cholinergic function after excitotoxic basal forebrain lesions in rat. Pharmacopsychiatry 32 (1999) 242-247
5. Aura J., Riekkinen M., and Riekkinen Jr. P. Tetrahydroaminoacridine and d-cycloserine stimulate acquisition of water maze spatial navigation in aged rats. Eur J Pharmacol 342 1 (1998) 15-20
6. Barnes C.A. Normal aging: regionally specific changes in hippocampal synaptic transmission. Trends Neurosci 17 (1994) 13-18
7. Barnes C.A., Meltzer J., Houston F., Orr G., McGann K., and Wenk G.L. Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors. Neuroscience 99 (2000) 17-23
8. Bartolini L., Casamenti F., and Pepeu G. Aniracetam restores object recognition impaired by age, scopolamine, and nucleus basalis lesions. Pharmacol Biochem Behav 53 2 (1996) 277-283
9. Bartus R.T., Dean R.L., Beer B., and Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science 217 (1982) 408-417
10. Beatty W.W., Buters N., and Janowsky D.S. Patterns of memory failure after scopolamine treatment: implications for cholinergic hypothesis of dementia. Behav Neural Biol 45 (1986) 196-211
11. Belluardo N., Mudo G., Blum M., and Fuxe K. Central nicotinic receptors, neurotrophic factor and neuroprotection. Behav Brain Res 113 (2000) 21-34
12. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 1 (2006) CD005593
13. Borst J.G.G., Leung L.-W.S., and MacFabe D.F. Electrical activity of the cingulated cortex: II. Cholinergic modulation. Brain Res 407 (1987) 81-93
14. Breese C.R., Adams C., Logel J., Drebing C., Rollins Y., Barnhart M., et al. Comparison of the regional expression of nicotinic acetylcholine receptor alpha7 mRNA and [125I]-alpha-bungarotoxin binding in human postmortem brain. J Comp Neurol 387 3 (1997) 385-398
15. Brenner R.P., Reynolds C.F., and Ulrich R.F. Diagnostic efficacy of computerized spectral versus visual EEG analysis in elderly normal, demented and depressed subjects. Electroencephalogr Clin Neurophysiol 69 2 (1988) 110-117
16. Brown R.E., Stevens D.R., and Haas H.L. The physiology of brain histamine. Prog Neurobiol 63 (2001) 637-672
17. Buyukuysal R.L., Ulus I.H., Aydin S., and Kiran B.K. 3,4-Diaminopyridine and choline increase in vivo acetylcholine release in rat striatum. Eur J Pharmacol 281 2 (1995) 179-185
18. Buzsaki G., Bickford R.G., Ponomareff G., Thal L.G., Mandel R., and Gager F.G. Nucleus basalis and thalamic control of neocortical activity in the freely moving rat. J Neurosci 8 (1988) 4007-4026
19. Cain D.P., Ighanian K., and Boon F. Individual and combined manipulation of muscarinic, NMDA, and benzodiazepine receptor activity in the water maze task: implications for a rat model of Alzheimer's dementia. Behav Brain Res 111 (2000) 125-137
20. Cape E.C., and Jones B.E. Effects of glutamate agonist versus procaine microinjections into the basal forebrain cholinergic cell area upon gamma and theta EEG activity and sleep-wake state. Eur J Neurosci 12 (2000) 2166-2184
21. Carelli V, Liberatore F, Scipione L, Rotiroti D, Rispoli V, Cardellini M, 2001. Choline derivatives for the treatment of Alzheimer's disease. Patent IT MI 2000 A000898-21-4-2000, EP 1925883.9- 10-4-2001; C.A.; 135(24): 344212m.
22. Casamenti F., Deffenu G., Abbamonti A., and Pepeu G. Changes in cortical acetylcholine output induced by modulation of nucleus basalis. Brain Res Bull 16 (1986) 689-695
23. Cassel J.C., and Jeltsch H. Serotoninergic modulation of cholinergic function in the central nervous system: cognitive implications. Neuroscience 69 (1995) 1-41
24. Celesia G.G., and Jasper H.H. Acetylcholine release from cerebral cortex in relation to state of activation. Neurology 16 (1966) 1053-1063
25. Collerton D. Cholinergic function and intellectual decline in Alzheimer's disease. Neuroscience 19 (1986) 1-28
26. Coyle A.J., Prince D.L., and De Long M.R. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 291 (1983) 1184-1190
27. Cuculic Z., Bost K., and Himwich H.E. An examination of a possible cortical cholinergic link in the EEG arousal reaction. Prog Brain Res 28 (1968) 27-39
28. Detari L., Rasmusson D.D., and Semba K. The role of basal forebrain neurons in tonic and phasic activation of the cerebral cortex. Prog Neurobiol 58 (1999) 249-277
29. Diez-Ariza M., Redondo C., Garcia-Alloza M., Lasheras B., Del Rio J., and Ramirez M.J. Flumazenil and Tacrine increase the effectiveness of ondansetron on scopolamine induced impairment of spatial learning in rats. Psycopharmacology 169 (2003) 35-41
30. Dixon M. Determination of enzyme-inhibitor constants. Biochem J 55 (1953) 170-171
31. Doody R.S., Steves J.C., Beck C., Dubinsky R.M., Kaie J.A., Gwyther L., et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurobiology 56 9 (2001) 1154-1166
32. Dringenberg H.C. Alzheimer's disease: more than a "cholinergic disorder" - evidence that cholinergic-monaminergic interactions contribute to EEG slowing and dementia. Behav Brain Res 115 (2000) 235-249
33. Ellman G.L., Courtney K.D., Andres V., and Featherstone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7 (1961) 88-95
34. Ennaceur A., and Delacour J. A new one-trial test for neurobiological studies of memory in rats: 1. Behavioral data. Behav Brain Res 31 1 (1988) 47-59
35. Erickson C.A., and Barnes C.A. The neurobiology of memory changes in normal aging. Exp Gerontol 38 (2003) 61-69
36. Fenton G.W. Electrophysiology of Alzheimer's disease. Br Med Bull 42 (1986) 29-33
37. Foster T.C. Involvement of hippocampal synaptic plasticity in age-related memory decline. Brain Res Rev 30 (1999) 236-249
38. Francis P.T., Palmer A.M., Snape M., and Wilcock G.K. The cholinergic hypothesis of Alzheimer's disease, a review of progress. J Neurol Neurosurg Psychiatry 66 (1999) 137-147
39. Funderbuck W.H., and Case T.J. The effect of atropine on cortical potentials. Electroencephalogr Clin Neurophysiol 3 (1951) 213-233
40. Geerts H. Indicators of neuroprotection with galantamine. Brain Res Bull 64 6 (2005) 519-524
41. Giacobini E. Cholinesterases: new role in brain function and Alzheimer's disease. Neurochem Res 28 3-4 (2003) 515-522
42. Haas H.L., and Panula P. The role of histamine and the tuberomammillary nucleus in the nervous system. Nat Rev Neurosci 4 (2003) 121-130
43. Helkala E.L., Laulumas V., Soikkeli R., Partanen J., Soininen H., and Riekkinen P.J. Slow-wave activity in the spectral analysis of the electroencephalogram is associated with cortical dysfunctions in patients with Alzheimer's disease. Behav Neurosci 105 3 (1991) 409-415
44. Holsheimer J. Generation of theta activity (RSA) in the cingulated cortex of the rat. Exp Brain Res 47 (1982) 309-312
45. Jakala P., Sirvio J., Jolkkonen J., Riekkinen P.J., Acsady L., and Riekkinen P. The effects of p-chlorophenylalanine induced serotonin synthesis inhibition and muscarinic blockade on the performance of rats in a 5-choice serial reaction time task. Behav Brain Res 51 (1992) 29-40
46. Jonnala R.R., Graham III J.H., Terry A.V., Beach J.W., Young J.A., and Buccafusco J.J. Synapse 47 (2003) 262-269
47. Katzman R. Medicinal progress in Alzheimer's disease. N Engl J Med 314 (1986) 964-973
48. Kihara T., Sawada H., Nakamizo T., Kanki R., Yamashita H., Maelicke A., et al. Galantamine modulates nicotinic receptor and blocks Aβ-enhanced glutamate toxicity. Biochem Biophys Res Commun 325 3 (2004) 976-982
49. Kopelman M.D., and Corn T.H. Cholinergic "blockade" as a model for cholinergic depletion. Brain 111 (1988) 1079-1110
50. Koppen A., Klein J., Erb C., and Loffelholz K. Acetylcholine release and choline availability in rat hippocampus: effects of exogenous choline and nicotinamide. J Pharmacol Exp Ther 282 3 (1997) 1139-1145
51. Krall W.J., Sramek J.J., and Cutler N.R. Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease. Ann Pharmacother 33 4 (1999) 441-450
52. Ladner C.J., and Lee J.M. Pharmacological treatment of Alzheimer's disease: the cholinergic hypothesis revisited. J Neuropathol Exp Neurol 57 (1998) 719-731
53. Locatelli T., Cirsi M., Liberati D., Franceschi M., and Comi G. EEG coherence in Alzheimer's disease. Electroencephalogr Clin Neurophysiol 106 (1998) 229-237
54. Maelicke A., and Albuquerque E.X. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. Eur J Pharmacol 393 (2000) 165-170
55. Maelike A., Samichocki M., Jostock R., Fehrenbacker A., Ludwig J., Albuquerque E.X., et al. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol Psychiatry 49 (2001) 279-288
56. Mandelzys A., De Koninck P., and Cooper E. Agonist and toxin sensitivities of ACh-evoked currents on neurons expressing multiple nicotinic ACh receptor subunits. J Neurophysiol 74 3 (1995) 1212-1221
57. Mann D.J., Alonso A., and Jones B.E. Discharge properties of justacellularly labelled and immunohistochemically identified cholinergic basal forebrain neurons recorded in association with the electroencephalogram in anesthetized rats. J Neurosci 20 (2000) 1505-1518
58. Metherate R., Cox C.L., and Ashe J.H. Cellular bases of neocortical activation: modulation of neural oscillation by the nucleus basalis and endogenous acetylcholine. J Neurosci 12 (1992) 4701-4711
59. Miyauchi T., Hagimoto H., Ishii M., Endo S., Tanaka K., Endo K., et al. Quantitative EEG in patients with presenile and senile dementia of the Alzheimer type. Acta Neurol Scand 89 1 (1994) 56-64
60. Moriguchi S., Marszalec W., Zhao X., Yeh J.Z., and Narahashi T. Mechanism of action of galantamine on N-methyl-d-aspartate receptors in rat cortical neurons. J Pharmacol Exp Ther 310 (2004) 933-942
61. Morris R.G.M. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11 1 (1984) 47-60
62. Muir J.L., Page K.J., Sirinathsinghji D.J.S., Robbins T.W., and Everitt B.J. Excitotoxic lesion of basal forebrain cholinergic neurons: effects on learning, memory and attention. Behav Brain Res 57 (1993) 123-131
63. Muir J.L., Everitt B.J., and Robbins T.W. AMPA-induced excitotoxic lesions of the basal forebrain: a significant role for the cortical cholinergic system in attentional function. J Neurosci 14 (1994) 2313-2326
64. Muir J.L., Everitt B.J., and Robbins T.W. Reversal of visual attentional dysfunction following lesions of the cholinergic basal forebrain by physostigmine and nicotine but not by 5-HT3 receptor antagonist ondansetron. Psychopharmacology 118 (1995) 82-92
65. Olin J., and Schneider L. Galantamine for Alzheimer's disease. Cochrane Database Syst Rev 4 (2001) CD001747
66. Page K.J., Everitt B.J., Robbins T.W., Marston H.M., and Wilkinson L.S. Dissociable effects on spatial maze and passive avoidance acquisition and retention following AMPA and ibotenic acid-induced excitotoxic lesions of the basal forebrain in rats: differential dependence on cholinergic neuronal loss. Neuroscience 43 (1991) 457-472
67. Papke R.L., Bencherif M., and Lippiello P. An evaluation of neuronal nicotinic acetylcholine receptor activation by quaternary nitrogen compounds indicates that choline is selective for the alpha 7 subtype. Neurosci Lett 213 3 (1996) 201-204
68. Paxinos G., and Watson C. The rat brain in the stereotaxic coordinates (1980), Academic Press, New York
69. Perry E.K., Perry R.H., Blessed G., and Tomlison B.E. Changes in brain cholinesterases in senile dementia of the Alzheimer type. Neuropathol Appl Neurobiol 4 (1978) 273-277
70. Pozzi D., Petracchi M., Sabe L., Golimstock A., Garcia H., and Starkstein S. Quantified electroencephalographic correlates of neuropsychological deficits in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 7 1 (1995) 61-67
71. Prichep I.S., John E.R., Ferds S.H., Reisberg B., Almas M., Alper K., et al. Quantitative EEG correlates of cognitive deterioration in elderly. Neurobiol Aging 15 (1994) 85-90
72. Racchi M., Mazzucchelli M., Porrello E., Lanni C., and Govni S. Acetylcholinesterase inhibitors: novel activities of old molecules. Pharmacol Res 50 (2004) 441-451
73. Riekkinen Jr. P., Jakala P., Sirvio J., Koivisto E., Miettinen R., and Riekkinen P. The effects of THA on scopolamine and nucleus basalis lesion-induced EEG slowing. Brain Res Bull 26 (1991) 633-637
74. Riekkinen Jr. P., Riekkinen M., Sirvio J., Miettinen R., and Riekkinen P. Loss of cholinergic neurons in the nucleus basalis induces neocortical electroencephalographic and passive avoidance deficits. Neuroscience 47 4 (1992) 823-831
75. Rispoli V., Rotiroti D., Carelli V., Liberatore F., Scipione L., Marra R., et al. Choline pivaloyl esters improve in rats cognitive and memory performances impaired by scopolamine treatment or lesions of the nucleus basalis of Meynert. Neurosci Lett 356 (2004) 199-202
76. Rispoli V., Rotiroti D., Carelli V., Liberatore F., Scipione L., Marra R., et al. Electroencephalographic effects induced by choline pivaloyl esters in scopolamine treated or nucleus basalis magnocellularis lesioned rats. Pharmacol Biochem Behav 78 (2004) 667-673
77. Samochocki M., Hoffle A., Fehrenbacker A., Jostock R., Ludwig J., Christener C., et al. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 305 (2003) 1024-1036
78. Santos M.D., Alkondon M., Pereira E.F., Arakova Y., Eisenberg H.M., Maelicke A., et al. The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. Mol Pharmacol 61 (2002) 1222-1234
79. Scali C., Casamenti F., Pazzagli M., Bartolini L., and Pepeu G. Nerve growth factor increases extracellular acetylcholine levels in the parietal cortex and hippocampus of aged rats and restores object recognition. Neurosci Lett 170 (1994) 117-120
80. Scali C., Giovannini M.G., Bartolini L., Prosperi C., Hinz V., Schmidt B.H., et al. Effect of metrifonate on extracellular brain acetylcholine levels and object recognition in aged rats. Eur J Pharmacol 325 (1997) 173-180
81. Scali C., Giovannini M.G., Prosperi C., Bartolini L., and Pepeu G. Tacrine administration enhances extracellular acetylcholine in vivo and restores the cognitive impairment in aged rats. Pharmacol Res 36 (1997) 463-469
82. Schneider L.S. Treatment of Alzheimer's disease with cholinesterase inhibitors. Clin Geriatr Med 17 2 (2001) 337-358
83. Semba K. The cholinergic basal forebrain: a critical role in cortical arousal. In: Napier T.C., Kalivas P.W., and Hanin I. (Eds). The basal forebrain: anatomy to function (1991), Plenum Press, New York 197-218
84. Stammelin J., Cassel J.C., Will B., and Kelche C. Sensitivity to cholinergic drug treatment of aged rats with variable degrees of spatial memory impairment. Behav Brain Res 98 (1999) 53-66
85. Steriade M., and Llinas R. The functional states of the thalamus and the associated neuronal interplay. Physiol Rev 68 (1988) 649-742
86. Steriade M., Gloor P., Llinas R.R., Lopes da Silva F.H., and Mesulam M. Basic mechanisms of the von Krosig cerebral rhythmic activities. Electroencephalogr Clin Neurophysiol 76 (1990) 481-508
87. Sunderland T., Tariot P., Murphy D.L., Weingartner H., Muller E.A., and Cohen R.M. Scopolamine challenges in Alzheimer's disease. Psycopharmacology 87 (1985) 247-249
88. Texido L., Ros E., Martin-Satue M., Lopez S., Aleu J., Marsal J., et al. Effect of galantamine on the human alpha7 neuronal nicotinic acetylcholine receptor, the Torpedo nicotinic acetylcholine receptor and spontaneous cholinergic synaptic activity. Br J Pharmacol 145 5 (2005) 672-678
89. Uteshev V.V., and Knot H.J. Dynamic in response to choline-mediated excitation in hystaminergic tuberomammillary neurons. Neuroscience 134 (2005) 133-143
90. Uteshev V.V., Meyer E.M., and Papke R.L. Regulation of neuronal function by choline and 40H-GTS-21 through α7-nicotinic receptors. J Neurophysiol 89 (2003) 1797-1806
91. Vanderwolf C.H., Raithby A., Snider M., Cristi C., and Tanner C. Effects of some cholinergic agonists on neocortical slow wave activity in rat with basal forebrain lesions. Brain Res Bull 31 (1993) 515-521
92. von Krosig M., Bal T., and McCormick D.A. Cellular mechanisms of a synchronized oscillation in the thalamus. Science 261 (1993) 361-364
93. Wang T., and Tany X.C. Reversal of scopolamine-induced deficits in radial maze performance by (-)- huperzine A: a comparison with E2020 and Tacrine. Eur J Pharmacol 349 (1998) 137-142
94. Wecker L. Choline utilization by central cholinergic neurons. In: Wurtman R.J., and Wurtman J.J. (Eds). Nutrition and the brain vol 8 (1990), Raven Press, New York 147-162
95. Whitehouse P.J., Price D.L., Clark A.W., Coyle J.T., and DeLong M.R. Alzheimer's disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 10 2 (1981) 122-126
96. Whitehouse P.J., Price D.L., Struble R.G., Clark A.W., Coyle J.T., and DeLong M.R. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 215 4537 (1982) 1237-1239
97. Yoshida S., and Suzuki N. Antiamnesic and cholinomimetic side effects of the cholinesterase inhibitors, physostgmine, taurine and NIK-247 in rats. Eur J Pharmacol 150 (1993) 117-124
98. Zhang Y., Ji Y., and Mei J. Effects of cholinergic agents on spontaneous activity of nucleus basalis magnocellularis neurons in different age rats. Neurosci Lett 288 2 (2000) 91-94